Diagnosis, Innovation

Do Alzheimer’s Blood Tests Replace the Need for Cognitive Screening?

Excitement about the effectiveness and availability of blood biomarker testing for Alzheimer’s disease (AD) has created confusion around whether there’s still a need for other important tools, like cognitive screening. The answer is simple. Cognitive screening is integral to monitoring brain function and identifying impairment in older adults. (But even cognitive screening makers like Neurotrack […]

Read more
Medication

Understanding Leqembi: 6 Things to Know About the New Alzheimer’s Drug

In a significant milestone for Alzheimer’s disease treatment, the U.S. Food and Drug Administration (FDA) recently approved the groundbreaking new drug, Leqembi. The medication is poised to bring new hope and treatment options to the more than 55 million people worldwide currently diagnosed with dementia or Alzheimer’s. To better understand Leqembi’s potential impacts, let’s unpack […]

Read more
From the CEO

The Brain Health Secrets I Want Everyone to Know

When the brilliant and talented Tina Turner passed after a long battle with kidney disease, one of her biggest regrets came to light. She hadn’t understood the link between high blood pressure and kidney health before it was too late, and she desperately wanted to raise awareness. We don’t get warnings like this from people […]

Read more
Diagnosis

How Inequity Creates Barriers to Cognitive Care for Women of Color

Cognitive care is no exception to the racial imbalances Black, Hispanic, Asian, and Native American individuals experience in healthcare. It is a well known fact that two-thirds of the American population living with Alzheimer’s are women, irrespective of race. Yet, they have also been historically underrepresented in clinical trials and face more barriers to accessing […]

Read more
Diagnosis

Barriers, Burnout, and Bottlenecks: Common Problems in Cognitive Care

With almost 50 million people worldwide affected by dementia—and Alzheimer’s disease the likely cause in 60% to 80% of these cases—detection and care is at a critical juncture. Despite high prevalence of cognitive disease, significant barriers, healthcare provider burnout, and systemic bottlenecks all interfere with their identification and treatment.  By exploring common problems in cognitive […]

Read more
Innovation

Neurotrack Expands C-suite with New Chief Growth Officer to Accelerate Partnerships in Health System and Provider Markets

New hire to drive business expansion amid exciting advances in Alzheimer’s treatment and care (PRESS RELEASE) Neurotrack, the leader in science-backed cognitive health solutions, announced Shawn Lemerise as its first Chief Growth Officer to support the company’s expanding business. With more than 20 years of healthcare experience, Shawn brings his expertise in the health system and provider […]

Read more